REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorWeill Medical College of Cornell University

About this trial

This is a research study in women to compare the outcomes of two procedures that restore blood flow to the arteries of the heart. In one procedure the blockages are ballooned and then stented with a small wire mesh tube through a small incision in the wrist or the groin. The other procedure is an open-heart operation in which healthy blood vessels from inside the chest, leg, and/or forearm are used to "bypass" the blockages (like a detour). Outcomes will be measured by comparing survival and improvement in quality-of-life.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female sex

Patient is at least 18 years old.

Multivessel or left main CAD is present for which revascularization is intended and for which there is equipoise between CABG and PCI according to local Heart Team assessment.

Ability to provide written informed consent and comply with all follow-up procedures, including QOL questionnaires.

Disqualifiers

ST-segment elevation MI within 3 days

Cardiogenic shock

Prior PCI within 1 year or any in-stent restenosis with diameter stenosis ≥50% or any prior cardiac surgery

Planned hybrid revascularization (PCI after CABG or CABG after PCI)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Coronary artery bypass grafting (CABG)

    Procedure/Surgery

    Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.

  • Percutaneous coronary intervention (PCI)

    Procedure/Surgery

    Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart

Treatment groups

600 Participants
are divided into 2 treatment groups
Group A: RECHARGE:Women - CABGOther 1 intervention
Group B: RECHARGE:Women - PCIOther 1 intervention

Trial outcomes

Primary outcomes

1

Hierarchical composite of all-cause death and time-averaged change from baseline in generic quality of life using the SF-12v2

Generic quality of life (QOL) will be assessed by utilizing the 12-item Short Form Survey (SF-12v2). The score ranges from 1-100, with higher scores indicating a better health status. The win ratio method will be utilized

Time frame
5 years

Secondary outcomes

1

Time averaged change from baseline in disease-specific quality of life using the SAQ-OS

Disease-specific quality of life (QOL) will be assessed by utilizing the Seattle Angina Questionnaire overall summary (SAQ-OS) score. The score ranges from 1-100, with higher scores indicating a better health status.

Time frame
5 years

Other outcomes

1

Time-averaged changes in PROMIS-29 Scores

The PROMIS-29 instrument measures pain intensity on a scale of 0-10 plus 7 health domains: pain interference, fatigue, sleep disturbance, depressive symptoms, anxiety, physical function, and ability to participate in social roles. Each of the 7 domains is scored separately, with the lowest score for an individual domain being 4 and the highest being 20. Pain intensity is scored on the scale from 1-10. A mean of 50 and a standard deviation of 10 represent the general US population. A T-score rescales the raw scores to standardized scores. For most measures, higher T-scores indicate more of the concept being measured, except for physical function, which is reverse-scored (lower scores indicate worse function).

Time frame
1 month, 3months, 6months, 12months and annually after procedure
2

Time-averaged changes in EQ5D-VAS Scores

The EQ5D-VAS records self-rated health status on a graduated visual analog scale (VAS) from 0-100, with higher scores for higher health-related quality of life. It also includes the EQ-5D descriptive system, which comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

Time frame
1 month, 3months, 6months, 12months and annually after procedure
3

Time-averaged changes in PHQ Scores

The Patient Health Questionnaire (PHQ-8) is an 8-item questionnaire used to diagnose and quantify the severity of depressive symptoms. It is designed to evaluate the overall QOL of the individual and questions are based on the diagnostic criteria for Major Depressive Disorder outlined in the Diagnostic and Statistical Manual, 5th Edition (DSM-5). The lowest score is 0 and the highest score is 24. Scores ≥10 suggest a substantial burden of depressive symptoms.

Time frame
1 month, 3months, 6months, 12months and annually after procedure
4

Time-averaged changes in MoCA scores

The telephone Montreal Cognitive Assessment (MoCA Blind or T-MoCA) is a tool to assess mild cognitive impairment. The MoCA BlindT-MoCA consists of 15 non-visual items that assesses different cognitive domains, including attention and concentration, memory, language, conceptual thinking, calculations, and orientation. The maximum score is 22 points with a score of 18 or below signifying mild cognitive dysfunction.

Time frame
1 month, 3months, 6months, 12months and annually after procedure

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Weill Medical College of Cornell University

Lead sponsor

Patient-Centered Outcomes Research Institute

Collaborator

Icahn School of Medicine at Mount Sinai

Collaborator